AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03006380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxytocin
Description: Ecbolic used to reduce blood loss
Study NCT03776747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prone hyperpolarized 3 helium gas scan
Description: Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is prone.
Study NCT03965689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03965689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT03965689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pevonedistat
Description: Given IV
Study NCT01219868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician-nurse team supervision
Description: Physician-nurse team will supervise patient's flow in the ED
Study NCT01921010 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Niaspan
Description: See Arm Description
Study NCT01921010 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: See Arm Description
Study NCT02336295 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Food Frequency Questionnaires
Description: filling a Food Frequency Questionnaires
Study NCT03711175 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Subscapularis repair
Description: Utilizing fiberwire, high tensile strength suture
Study NCT03711175 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Shoulder implant
Description: Reverse shoulder arthroplasty device
Study NCT03776747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Supine hyperpolarized 3 helium gas scan
Description: Hyperpolarized gas used as a contrast agent to test reproducibility of MRI of the lungs/Images done while subject is supine.
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vitals
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Vitals
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Pulmonary Function Tests
Description: Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Function Tests
Description: Pre and post spirometry, diffuse lung carbon monoxide (DLCO), lung volumes
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Initial protocol MRI scan
Description: Initial scan to determine placement
Study NCT03776747 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Initial protocol MRI scan
Description: Initial scan to determine placement
Study NCT03373149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone/HPuFSH/GnRH antagonist
Description: Growth hormone (Somatropin, Sedico, Egypt) \[4 IU/day\] and highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Study NCT03373149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HPuFSH/GnRH antagonist
Description: Highly purified urinary FSH (HPuFSH) (Fostimon,IBSA, Switzerland) \[300 IU/day\] will be started on cycle day 3 and will be continued until and including the day of human chorionic gonadotropin (HCG) administration. Starting from cycle day 8, the dose of HPuFSH will be adjusted individually according to ovarian response which will be monitored using transvaginal ultrasound and serum estradiol (E2).~GnRH antagonist (Cetrorelix acetate) (Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25 mg S.C. once daily will be started when the leading follicle is 14 mm in mean diameter and will be continued until and including the day of HCG administration.
Study NCT03594682 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention/treatment
Description: experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd
Study NCT03594682 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention/treatment
Description: experimentalgroup initial dose：~1. 250mg qod~2. 250mg qd/500mg qd by turn~3. 500mg qd control group： 750mg qd
Study NCT00763386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen LPS-Flex Fixed Bearing Knee
Description: NexGen LPS-Flex Fixed Bearing femoral component
Study NCT00732589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% xylocaine
Description: 10 cc. of 1%xylocaine, once a week
Study NCT00763386 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen Legacy Posterior Stabilized Knee
Description: NexGen Legacy Posterior Stabilized femoral component
Study NCT03567031 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EtCO2 modification
Description: Controlled modification of EtCO2 through modification of ventilation parameters under general anesthesia without spontaneous breathing
Study NCT00732589 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: ultrasound at shoulder area about 10 mins.
Study NCT01696669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: * Vincristine, 2 mg/m\^2 IV bolus, day 1.~* Doxorubicin: 75 mg/m\^2 per cycle, or 25 mg/m\^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).~* Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.~* Cyclophosphamide: 2100 mg/m\^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.~* MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.~* G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm\^3/L.~* Ifosfamide: 1800 mg/m\^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m\^2 total maximum dose).~Window phase in high-risk patients (21-days cycle):~* Gemcitabine: 1000 mg/m\^2 IV, 90 minutes on day 1 and 8.~* Docetaxel 100 mg/m\^2, 2-3 hour infusion on day 8.
Study NCT01696669 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Surgical intervention aiming to completely resect the tumor with negative margins.
Study NCT01696669 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response \<90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
Study NCT05851833 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early Mobilization
Description: The time the patient began to sit, stand, and walk after surgery is earlier than traditional model.
Study NCT01757314 — intervention group
Intervention type: BEHAVIORAL
Intervention: ultrasound technique
Description: instruction in the ultrasound technique
Study NCT01757314 — intervention group
Intervention type: OTHER
Intervention: palpation technique
Description: placement of a line via palpation technique
Study NCT01573546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
Study NCT01573546 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
Study NCT01573546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Health education control
Description: The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
Study NCT02669342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiance™ Clear Sharklet® Silicone Foley Catheter
Study NCT02461329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusine® B. Braun
Description: Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
Study NCT03276208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prenatal Massage
Description: We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
Study NCT03276208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
Study NCT03276208 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
Study NCT02360332 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project SEARCH plus ASD Supports
Description: Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
Study NCT01272206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2011
Description: Administered as one single i.v. (intravenous) injection, 100 mcg/kg
Study NCT02461329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ringerfundin ® B. Braun
Description: Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
Study NCT01272206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC 0128-0000-2021
Description: Administered as one single i.v. (intravenous) injection, 100 mcg/kg
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Cladribine
Description: Cladribine is a purine antimetabolite indicated for the treatment of relapsing forms of multiple sclerosis, to include relapsing-remitting disease and active secondary progressive disease, in adults.
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Dimethyl fumarate
Description: Dimethyl fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Fingolimod
Description: Fingolimod is a sphingosine 1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis to reduce the frequency of clinical exacerbations and to delay the accumulation of physical disability.
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Teriflunomide
Description: Teriflunomide is a pyrimidine synthesis inhibitor indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Ozanimod
Description: Ozanimod is a sphingosine-1-phosphate receptor modulator indicated for the treatment of patients with relapsing forms of multiple sclerosis.
Study NCT04676204 — intervention group
Intervention type: DRUG
Intervention: Diroximel fumarate
Description: Diroximel fumarate is indicated for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Study NCT03897335 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aminophylline
Description: Aminophylline pre cardiopulmonary bypass and immediately post cardiopulmonary bypass. The dose will be Aminophylline 5 mg/kg/dose, max 350 mg slow infusion. The infusion rate duration will be standardized to 20 minutes. There will be no other aminophylline treatments for the first post-op five days.
Study NCT03897335 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group will not receive any aminophylline treatments for the first post-op five days
Study NCT05189002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin 40 mg
Description: Dimolegin - DD217 - 40 mg
Study NCT05189002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimolegin 60 mg
Description: Dimolegin - DD217 - 60 mg
Study NCT05189002 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fragmin
Description: Fragmin 5000 IU in 0.2 ML Prefilled Syringe
Study NCT00587665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: Single IV dose of 0.1 mg/kg of ketamine
Study NCT00587665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline given of equal volume to drug
Study NCT02199574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL
Description: 133 mg EXPAREL in 10 mL.
Study NCT00891813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zemplar (paricalcitol)
Description: Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
Study NCT00255580 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Smoked cannabis
Study NCT00255580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Smoked cannabis
Study NCT01491516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System
Description: The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
Study NCT04221971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy combined with NK cells infusion
Description: chemotherapy combined with NK cells infusion
Study NCT02669342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silicone Foley Catheter
Study NCT00381004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Course 1: 250 mg/m\^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
Study NCT00381004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Course 1: 25 mg/m\^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m\^2 by vein over 5-30 minutes on Days 1 - 3
Study NCT00381004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Course 1: 250 mcg/m\^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m\^2 SQ on Days -1 and Days 4 - 10
Study NCT00381004 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Course 1: 375 mg/m\^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m\^2 by vein over 2-6 Hours on Day 1
Study NCT00062179 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: carboplatin
Description: Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
Study NCT00062179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
Study NCT01622114 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women
Description: 2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
Study NCT01622114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women
Description: 2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
Study NCT04289168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Music class was provided for the intervention group
Study NCT02217579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: A food containing 5 grams/serving of supplemental protein.
Study NCT02471339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
Study NCT02471339 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Acceptance and Commitment Therapy (ACT)
Description: Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
Study NCT02340455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin_male
Description: Pregabalin 150mg bid 1day Men
Study NCT02340455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin_female
Description: Pregabalin 150mg bid 1day Women
Study NCT02340455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo_Men
Description: Placebo durg
Study NCT02340455 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo_Women
Description: Placebo_Women
Study NCT04035616 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: microbial cell preparation [MCP]
Description: active microbial cell preparation
Study NCT04035616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: inactive ingredient
Study NCT04075448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: 100 grams breakfast cereal
Study NCT04075448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50 g Walnut
Description: 50 grams walnuts mixed with 50 gram breakfast cereal.
Study NCT02217579 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic fiber
Description: A food containing 8 grams/serving of supplemental prebiotic fiber.